Journal Article

By Any Other Name: Ambiguity in Marketing Proprietary Anti-Infective Agents

Stephen A. Berger

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 44, issue 1, pages 65-68
Published in print January 2007 | ISSN: 1058-4838
Published online January 2007 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/509929
By Any Other Name: Ambiguity in Marketing Proprietary Anti-Infective Agents

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

In 55 instances, a single proprietary (trade) name has been used to market ⩽ 2 distinct generic anti-infective agents. In some cases, one trade name represents 2 different drugs in the same country—or even marketed by the same manufacturer. Some unrelated drugs and poisonous substances are also manufactured under trade names assigned to anti-infectives. The use of proprietary names in the prescribing of anti-infective drugs could result in considerable confusion or harm to patients.

Journal Article.  578 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.